Tablets & Capsules July 2017 23
References
R. Mestel, "The Colorful History of Pills Can Fill
Many a Tablet," Los Angeles Times, Mar 25, 2002.
"Guidance for Industry: PAT–A Framework for
Innovative Pharmaceutical Development, Manufacturing,
and Quality Assurance," U.S. Department of Health and
Human Services, Food and Drug Administration, Center
for
Drug Evaluation and Research (CDER), Center for
Veterinary Medicine (CVM), Office of Regulatory Affairs
(ORA), Pharmaceutical CGMPs, September 2004.
"Pharmaceutical cGMPs for the 21st Century: A
Science and Risk Based Approach." FDA. Online. Accessed
May 25, 2017.
M. Glodek et al., "Process Robustness–A PQRI White
Paper," Pharm Eng 2008 26(26): 1-11.
R. Iser and A. Srinivasan, "FDA Perspectives: Common
Deficiencies in Abbreviated New Drug Applications: Part
1: Drug Substance," Pharm Tech 2010 34:1.
J. Piriou, B. Elissondo, M. Hertschuh, and R. Ollivier,
"Control Strategy as the Keystone of the Product
Lifecycle, from Product/Process Understanding to
Continuous Process Verification and Understanding,"
Pharm Eng 2012 2(1): 1-8.
J.F. Skaftason and T. Johannesson, "Tablets and Tablet
Production–with Special Reference to Icelandic
Conditions," Laeknabladid 2013 99(4): 197-202.
G.A. Van Buskirk et al, "Best Practices for the
Development, Scale-up and Post-Approval Change
Control of IR and MR Dosage Forms in the Current
Quality-by-Design Paradigm," AAPS PharmSciTech 2014
15(3): 665-693.
LX Yu et al, "Understanding Pharmaceutical Quality
by Design," AAPS J 2014 16(4): 771-783.
T. Mire-Stuis, B. Kuhn, and T. Monica, "Development
of Integrated Control Strategies and PV Plans for US and
European Filings," CASSS CMC Strategy Forum Europe,
2014.
S. Pope-Miksinski, "Regulatory Considerations in the
Development and Communication of Control Strategy,"
CMC Workshop, ONDP, FDA, 13 April 2015.
S. Pope-Miksinski, "Integrated Quality Assessment: An
Update on Team-Based and One Quality Voice," DIA
CMC Workshop, ONDP, FDA, 14 April 2015.
R. Iser, "Life-Cycle Management–FDA Perspective,"
Office and Process and Facilities, OPQ, FDA, DIA CMC
Workshop, April 13-15 2015, Bethesda, MD.
Risk Ranking and Filtering, PQRI, Risk Management
Training Guides, Manufacturing Technology Committee–
Risk Management Working Group, pp 1-8.
Robert J. Timko, RPh, PhD, is president of RhoTau Pharma Ser-
vices, 920 Sassafras Circle, West Chester, PA 19382. Tel. 484 437
2654. Website: www.RhoTauPharma.com. His consulting work
focuses on helping companies optimize their development and supply
chain footprints leading to successful product commercialization. He
has more than 40 years of industry experience in developing a variety
of dosage forms from both pharmaceutical development and regula-
tory affairs perspectives.
Further reading
To find more information about the topics discussed
here, search for articles listed under "Excipients,"
"Formulation," and "Quality by Design" in Tablets & Capsules'
article index in the November 2016 issue and at T&C's
website, www.tabletscapsules.com.
e xperts alik s and e beginner
͕ ŵ Ă Ğ ƚ Ő Ŷ ŝ ƌ Ƶ ƚ Đ Ă Ĩ Ƶ Ŷ Ă ŵ Ğ ƌ Ɵ Ŷ Ğ Ğ Ś ƚ ƌ Ž &
-learning E
sule Cap & t able Table
erful w o P
T
Individuals or groups
can select on-line
training topics and
training topics and
ƌĞĐĞŝǀĞĂĐĞƌƟĮĐĂƚĞ
ŽĨĐŽŵƉůĞƟŽŶ
ƚĞĐŚĐĞƵƟ
ƟĐĂůƐ͘ĐŽŵ
